These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 13841661

  • 1. Investigation of the activity of cytoxan against leukemia L1210 in mice.
    VENDITTI JM, HUMPHREYS SR, GOLDIN A.
    Cancer Res; 1959 Oct; 19():986-95. PubMed ID: 13841661
    [No Abstract] [Full Text] [Related]

  • 2. Some effects of cyclophosphamide (cytoxan) on normal mice and mice with L1210 leukemia.
    LANE M.
    J Natl Cancer Inst; 1959 Dec; 23():1347-59. PubMed ID: 14413840
    [No Abstract] [Full Text] [Related]

  • 3. Pathology of the spread of L1210 leukemia in the central nervous system of mice and effect of treatment with Cytoxan.
    THOMAS LB, CHIRIGOS MA, HUMPHREYS SR, GOLDIN A.
    J Natl Cancer Inst; 1962 Jun; 28():1355-89. PubMed ID: 13920822
    [No Abstract] [Full Text] [Related]

  • 4. Effectiveness of Cytoxan against intracerebrally and subcutaneously inoculated mouse lymphoid leukemia L1210.
    CHIRIGOS MA, HUMPHREYS SR, GOLDIN A.
    Cancer Res; 1962 Feb; 22():187-95. PubMed ID: 13879017
    [No Abstract] [Full Text] [Related]

  • 5. THE CORRELATION BETWEEN TRANSPLANTED MOUSE AND HUMAN ACUTE LEUKEMIAS.
    BURCHENAL JH, OETTGEN HF, LYMAN M, PURPLE J.
    Acta Unio Int Contra Cancrum; 1964 Feb; 20():256-9. PubMed ID: 14151900
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the effectiveness of Tetramin and its components against advanced leukemia L1210 in mice.
    VENDITTI JM, GOLDIN A, KLINE I.
    Cancer Chemother Rep; 1961 Apr; 11():73-6. PubMed ID: 13780696
    [No Abstract] [Full Text] [Related]

  • 7. Studies on the effectiveness of 4',4"-di-2-imidazolin-2-ylterephthalanilides against mouse leukemia L1210 and resistant variants.
    VENDITTI JM, GOLDIN A, KLINE I.
    Cancer Chemother Rep; 1962 Jun; 19():5-11. PubMed ID: 13925303
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. II.
    GOLDIN A, VENDITTI JM, KLINE I, MANTEL N.
    Cancer Res; 1960 Jun; 20(5)Pt 2():382-469. PubMed ID: 13850662
    [No Abstract] [Full Text] [Related]

  • 9. The influence of treatment schedule on the chemotheapy of advanced leukemia L1210 in mice.
    VENDITTI JM, GOLDIN A, KLINE I.
    Cancer Chemother Rep; 1960 Feb; 6():55-7. PubMed ID: 13841660
    [No Abstract] [Full Text] [Related]

  • 10. Studies of inhibitory effects of terephthalanilide derivatives against several variants of leukemia L1210.
    LAW LW.
    Cancer Chemother Rep; 1962 Jun; 19():13-8. PubMed ID: 14462961
    [No Abstract] [Full Text] [Related]

  • 11. Development of a leukaemia resistant to cyclophosphamide ('Cytoxan').
    LANE M, YANCEY ST.
    Nature; 1960 Nov 26; 188():756-7. PubMed ID: 13758721
    [No Abstract] [Full Text] [Related]

  • 12. CHEMOTHERAPY OF ADVANCED MOUSE LEUKEMIA L1210: COMPARISON OF METHOTREXATE ALONE AND IN SEQUENTIAL THERAPY.
    VENDITTI JM, GOLDIN A.
    Cancer Res; 1964 Sep 26; 24():1457-60. PubMed ID: 14221802
    [No Abstract] [Full Text] [Related]

  • 13. AN EXPERIMENTAL THERAPEUTIC APPROACH TO L1210 LEUKEMIA IN MICE: COMBINED CHEMOTHERAPY AND CENTRAL NERVOUS SYSTEM IRRADIATION.
    JOHNSON RE.
    J Natl Cancer Inst; 1964 Jun 26; 32():1333-41. PubMed ID: 14191403
    [No Abstract] [Full Text] [Related]

  • 14. EXPERIMENTAL CHEMOTHERAPY STUDIES. V. THE COLLATERAL SENSITIVITY TO ALKYLATING AGENTS OF SEVERAL ANTIMETABOLITE-RESISTANT ASCITES TUMORS IN MICE.
    RUTMAN RJ.
    Cancer Res; 1964 May 26; 24():634-8. PubMed ID: 14188466
    [No Abstract] [Full Text] [Related]

  • 15. CHEMOTHERAPEUTIC EFFECTS ON MAMMALIAN TUMOR CELLS. I. MODIFICATION OF LEUKEMIA L1210 GROWTH KINETICS AND KARYOTYPE WITH AN ALKYLATING AGENT.
    JOHNSON RE, ZELEN M, KEMP NH.
    J Natl Cancer Inst; 1965 Feb 26; 34():277-90. PubMed ID: 14293793
    [No Abstract] [Full Text] [Related]

  • 16. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.
    Schmid FA, Hutchison DJ.
    Cancer Res; 1972 Apr 26; 32(4):808-12. PubMed ID: 5014791
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacology of 3,5-diamino-1,24-triazole (guanazole). 1. Antitumor activity of guanazole.
    Hahn MA, Adamson RH.
    J Natl Cancer Inst; 1972 Mar 26; 48(3):783-90. PubMed ID: 4621741
    [No Abstract] [Full Text] [Related]

  • 18. HYDROXYUREA. A NEW TYPE OF POTENTIAL ANTITUMOR AGENT.
    STEARNS B, LOSEE KA, BERNSTEIN J.
    J Med Chem; 1963 Mar 26; 6():201. PubMed ID: 14188794
    [No Abstract] [Full Text] [Related]

  • 19. THE EFFECT OF A PHTHALANILIDE DERIVATIVE ON LIPIDE METABOLISM IN L1210 LEUKEMIA CELLS.
    GELLHORN A, WAGNER M, RECHLER M, KOREN Z, BENJAMIN W.
    Cancer Res; 1964 Apr 26; 24():400-8. PubMed ID: 14147813
    [No Abstract] [Full Text] [Related]

  • 20. HYDROXYMETHYLGLYOXAL BISGUANYLHYDRAZONE.
    LOO TL, DION RL, DAVIDSON JD, ADAMSON RH.
    J Med Chem; 1963 Nov 26; 6():819-20. PubMed ID: 14184964
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.